Exicure to Present Poster at SID 2019 Annual Meeting Demonstrating Bi-Specific Gene Targeting in Dermatology

May 9, 2019

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at the Society for Investigative Dermatology (SID) Meeting, May 8-11, in Chicago. The poster, titled, “Topically-applied bispecific nanoconstructs concurrently targeting TNFA and IL17RA reverse psoriasis-like changes in the imiquimod-induced psoriasis mouse model,” will be presented by Haoming Liu of the Northwestern Skin Disease Research Center at Northwestern University, which is directed by Exicure Advisory Board Member Amy Paller, M.D.

Session Date/Time: Saturday, May 11, 12:45 – 2:45 p.m. CT
Poster session: 3

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure’s proprietary SNA™ architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190509005878/en/

Source: Exicure, Inc.

MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com